Ribociclib - OmicsDI

Show results for

Unknown (335)
Genomics (56)
Transcriptomics (31)
Metabolomics (8)
Clinical (3)
Models (1)
Other (1)
Multiomics (1)
Proteomics (1)

Organisms

Homo sapiens (39)
Mus musculus (3)
Cytomegalovirus (1)
Rhadinovirus (1)
Lymphocryptovirus (1)
Merkel cell polyomavirus (1)
JC polyomavirus (1)
Betapolyomavirus hominis (1)
Human alphaherpesvirus 2 (1)
Betapolyomavirus macacae (1)
Human alphaherpesvirus 1 (1)
Human immunodeficiency virus 1 (1)
Citrobacter rodentium ICC168 (1)
Leymus chinensis (1)
Emiliania huxleyi CCMP371 (1)
Eulimnogammarus vittatus (1)
Escherichia coli KO11FL (1)
Cronobacter sakazakii (1)
Lactobacillus delbrueckii (1)
Brassica rapa var. rapa (1)
Carboxydothermus ferrireducens DSM 11255 (1)
Methanobrevibacter smithii ATCC 35061 (1)
Paulinella chromatophora (1)
Peromyscus eremicus (1)
Synechococcus sp. (1)
Drosophila erecta (1)
Drosophila simulans (1)
Drosophila persimilis (1)
Cryptosporidium parvum x Cryptosporidium tyzzeri (1)
Treponema pallidum subsp. pallidum (1)

Organisms

Homo sapiens (39)
Mus musculus (2)
Rattus norvegicus (1)

Repository

ENA (47)
geo (34)
MetaboLights (8)
EGA (5)
BioModels (1)
biostudies-arrayexpress (1)
EVA (1)
LINCS (1)
pride (1)

Tissue

Permanent cell line cell (1)
Cell culture (1)

Disease

Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma (1)
Colorectal Neoplasms (1)
Prostate cancer (1)

Technology Type

Mass spectrometry (4)
Mass spectrometry assay (4)
KINOMEscan (1)
Fluorescence intensity (1)
Mass Spectrometry (1)
Shotgun proteomics (1)

Instrument Platform

Liquid Chromatography MS - alternating - reverse-phase (2)
Liquid Chromatography MS - positive - reverse-phase (2)
Liquid Chromatography MS - negative - reverse-phase (2)
Liquid Chromatography MS - negative - reverse phase (2)
Liquid Chromatography MS - positive - reverse phase (2)
NextSeq 550 (1)
Illumina HiSeq 2000 (1)
MicrOTOF-Q II ESI-Qq-TOF (Bruker) (1)
Exactive (Thermo Scientific) (1)

Publication Date

2025 (11)
2026 (8)
2023 (6)
2019 (6)
2024 (4)
2021 (3)
2018 (2)
2022 (2)
2020 (2)
2017 (2)
2015 (1)

Metabolite Name

Ribociclib (8)
Dodecanedioic acid (7)
(1xi,3xi)-1,2,3,4-Tetrahydro-1-methyl-beta-carboline-3-carboxylic acid (6)
N-Acetylvaline (6)
Cholesterol sulfate (6)
2-Methylhippuric acid (6)
Ketoleucine (6)
Ile-Val-Val (6)
Arachidonic acid (6)
Riboflavin (6)
Hexadecanedioic acid (6)
Azelaic acid (6)
FAD (6)
Pseudouridine (6)
Sampatrilat (5)
Virginiamycin m1 (5)
LysoPG(18:1(9Z)/0:0) (5)
N-Palmitoyl Threonine (5)
N-Palmitoyl Valine (5)
N-Palmitoyl Alanine (5)
2-Dodecylbenzenesulfonic acid (5)
Hydroxyoctadecadienoic acid (5)
Miltirone (5)
3-Hydroxytetradecanoic acid (5)
2-Ethyl-1-hexanol sulfate (5)
N-Lactoylleucine (5)
4-Hydroxyquinoline (5)
(S)-3-Octanol glucoside (5)
LysoPE(18:0/0:0) (5)
Pentadecanoylglycine (5)

IsPrivate

False (1)

First Public Date

2025 (12)
2019 (9)
2023 (8)
2026 (4)
2020 (4)
2024 (3)
2021 (3)
2022 (2)
2018 (2)

Modelling Approach

Ordinary differential equation model (1)

Study status

Active, not recruiting (1)
Terminated (1)
Recruiting (1)

Study type

Interventional (3)
RNA-seq of coding RNA (1)

Release Date

2025 (67)
2024 (48)
2022 (41)
2023 (39)
2021 (33)
2020 (25)
2019 (22)
2018 (21)
2026 (16)
2017 (16)
2016 (4)
2015 (4)

Lab affiliation

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA Graduate Program in Cellular and Molecular Pharmacology, Graduate School of Biomedical Sciences, Rutgers (1)

Location

Germany (3)
Spain (3)
Belgium (3)
United States (3)
Hong Kong (2)
Singapore (2)
Australia (2)
Japan (2)
Oceania (1)
Taiwan (1)
Asia except Japan (1)
Europe (1)
North America (1)
Turkey (1)
Russia (1)
Canada (1)
China (1)
Netherlands (1)
Italy (1)
France (1)
South Korea (1)

Keyword

TMT212 (2)
Ribociclib (2)
Trametinib (2)
TNO155, spartalizumab, ribociclib, checkpoint inhibitor, SHP2, PD-1, CDK4/6, NSCLC, CRC, HNSCC, KRAS, esophageal SCC, GIST (1)
Mekinist (1)
Kisqali (1)
LEE011 (1)
KRAS-mutant colorectal cancer (1)
Metastatic pancreatic cancer (1)
Advanced pancreatic cancer (1)
JDQ443 (1)
Targeted therapy (1)
KRAS G12C (1)
CRC (1)
Spartalizumab (1)
Cetuximab (1)

Previous page
1 / 44
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 44
Next page

Sort by:

Relevance

Page size

Transcriptional profiling of ribociclib-treated sensitive and ribociclib resistant CAMA-1 cells

PRJNA602306 | ENA

HTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones

Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes ...

ORGANISM(S): Homo sapiens

2026-06-17 | E-MTAB-15265 | biostudies-arrayexpress

Effect of ribociclib on breast cancer cells

PRJNA755676 | ENA

Transcriptional profiling of ribociclib-treated sensitive and ribociclib resistant CAMA-1 cells

We report transcriptional response to ribociclib treatment in resistant and sensitive CAMA-1 cells using RNA sequencing. Acquired ribociclib resistant cells were generated by treating CAMA-1 cells over a period of 5 month. Cells were then treated with ribociclib or DMSO control and processed for RNA...

ORGANISM(S): Homo sapiens

2020-06-22 | GSE143944 | GEO

Effect of ribociclib on breast cancer cells

To study mechanisms underlying response to ribociclib.

ORGANISM(S): Homo sapiens

2022-01-10 | GSE182288 | GEO

Single-cell RNA-sequencing of Ribociclib treated mTECs

PRJNA1027913 | ENA

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (LEANORA)

PRJNA1159914 | ENA

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (LEANORA)

PRJNA1159915 | ENA